Gene therapy for augmentation chemosentivities to anticancer drugs with improvement of therapeutic index
Gene therapy for augmentation chemosentivities to anticancer drugs with improvement of therapeutic index
批准号:
10470265
负责人:
TANIGAWA Nobuhiko
金额:
$4.1万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B).
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Novel approaches are being investigated for improvement of therapies of human cancers. We have identified a strong association between sensitivity to 5-FU and levels of thymidine phosphorylase (TP) and thymidine kinase (TK) in either human gastric or colon cancer. In addition, after TP/PD-ECGF cDNA was successfully transfected into PC9 cells with use of a plasmid vector, the in vitro mechanism of augmentation of sensitivities to Doxifluridine and 5-FU was partly clarified, by use of the transfected cells, with obtaining confirmatory data of a bystander effect of a type of cell attachment included in the augmentation. A part of our research works, collaborating with the Department of Bacteriology I in Tokyo Jikeikai Medical College, firstly succeeded in yielding a retroviral vector involving TP/PD-ECGF cDNA and we are now conducting the investigation for further clarification of augmentation mechanism of chemosensitivities to Fluoro-pyrimidines. In the mean time, the level of TP enzyme, one of angiogenic peptides, is drastically decreased in both peritoneal seeding cells and in vitro cancer cells. Taken together, it can be considered that this newly developed retroviral vector involving TP/PD-ECGF cDNA may be substantially useful for study of tumor angiogenesis. Thus, the study of a virally directed enzyme prodrug therapy like this would have potential to propose invaluable methods for improvement of cancer chemotherapies.
期刊论文(78)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
M.Ohtani: "Impact of expression of cyclin-dependent kinase inhibitor p27k^<klrl> and apoptosis in tumor cells on overall survival of patients with non-early gastric carcimoma" Cancer. (in press).
M.Ohtani:“细胞周期蛋白依赖性激酶抑制剂 p27k^<klrl> 的表达和肿瘤细胞凋亡对非早期胃癌患者总体生存的影响”癌症。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M.Ohtani: "Impact of the expression of cyclin-dependent kinase inhibitor p27^<kip1> and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma"Cancer. 85(8). 1711-1718 (1999)
M.Ohtani:“细胞周期蛋白依赖性激酶抑制剂 p27^<kip1> 的表达和肿瘤细胞凋亡对非早期胃癌患者总体生存的影响”癌症。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Tenjyo: "Prognostic significance of p27^<kip1> protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas"Oncology. 58. 45-51 (2000)
T.Tenjyo:“结直肠腺癌患者中 p27^<kip1> 蛋白表达和自发性细胞凋亡的预后意义”肿瘤学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
C-D.Lu: "Loss of p27^<kip1> expression independently predicts poor prognosis for resectable pancreatic adenocarcinomas"Cancer. 85. 1250-1260 (1999)
C-D.Lu:“p27^<kip1> 表达的缺失独立预测可切除胰腺腺癌的不良预后”癌症。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Shinohara: "Intensified regression of colon cancer liver metastases in mice treated with irinotecan and the immunomodulaor JBT 3002."J.Immunotherapy. 23. 321-331 (2000)
H.Shinohara:“用伊立替康和免疫调节剂 JBT 3002 治疗的小鼠结肠癌肝转移得到强化消退。”J.Immunotherapy。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 27 条
In vitro chemosensitivity test to predict chemosensicivity for paclitaxel, using human gastric carcinoma tissues.
-
批准号:16209041
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$30.95万
-
财政年份:2004
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Medical treatment research by the gene cluster (EPR-1, dCK, and TP) which guides antineoplastic drug susceptibility reinforcement
-
批准号:13470262
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.86万
-
财政年份:2001
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Prediction of recurrence or metastasis of malignant tumors by assessment of their growth abilities and its clinical application
-
批准号:03454316
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$2.5万
-
财政年份:1991
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Application of a new drug screening method for clinical chemotherapy
-
批准号:63870051
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$3.78万
-
财政年份:1988
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Modification of Anti-cancer Drug Formula and Its Local Administration
-
批准号:63480301
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$2.3万
-
财政年份:1988
-
负责人:TANIGAWA Nobuhiko
-
依托单位: